Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Henning Rattunde"'
Autor:
Masakazu Haneda, Takashi Kadowaki, Nobuya Inagaki, Yasuo Terauchi, Atsushi Taniguchi, Uli C. Broedl, Kazuki Koiwai, Henning Rattunde, Hans-Juergen Woerle
Publikováno v:
Advances in Therapy. 32:306-318
The aim of this randomized, double-blind, parallel-group study was to investigate the safety and efficacy of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes (T2DM). In a 12-week dose-finding period, patients [N = 547;
Autor:
Jenny Manassie, Ambrish Mithal, Hans-Juergen Woerle, Uli C. Broedl, Henning Rattunde, Anthony H. Barnett, Russell Jones
Publikováno v:
The Lancet Diabetes & Endocrinology. 2:369-384
Diabetes is a leading cause of chronic kidney disease (CKD) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macrovascular complications and to slow the progression of CKD. W
Autor:
Atsushi Taniguchi, Kazuki Koiwai, Takashi Kadowaki, Masakazu Haneda, Hans-Juergen Woerle, Henning Rattunde, Nobuya Inagaki, Yasuo Terauchi, Uli C. Broedl
Publikováno v:
Advances in therapy. 31(6)
This study was designed to determine the efficacy and tolerability of empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus (T2DM). Patients with glycosylated hemoglobin (HbA1c) ≥7.0–≤10% were randomized via an interactiv
Autor:
Hans-Juergen Woerle, Uli C. Broedl, V. Seshiah, Russell Jones, R. Swallow, Henning Rattunde, Christopher S. Kovacs
Publikováno v:
Diabetes, obesitymetabolism. 16(2)
Aims This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients with type 2 diabetes (T2DM). Methods Patients with HbA1c ≥7 and ≤10% were randomized and treated with once daily empagl
Autor:
Claudio Gimpelewicz, Ashkay Desai, William T. Abraham, Albert Kandra, Kenneth Dickstein, Lars Køber, Bernard Reimund, Barry M. Massie, Juergen Armbrecht, John J.V. McMurray, Henning Rattunde, Henry Krum
Publikováno v:
European journal of heart failure. 13(1)
Aims The renin–angiotensin–aldosterone system (RAAS) represents a key therapeutic target in heart failure (HF) management. However, conventional agents that block this system induce a reflex increase in plasma renin activity (PRA), which may lead
Autor:
Henning Rattunde, K. Ludwig, Ralph Kickuth, Daniel Inderbitzin, Jiirgen Triller, Jürgen Gschossmann
Publikováno v:
Journal of vascular and interventional radiology : JVIR. 19(9)
Purpose To evaluate the efficacy of superselective embolization therapy in the management of acute lower gastrointestinal (LGI) hemorrhage, including any bleeding distal to the ligament of Treitz. Materials and Methods Between June and August 2007, 2
Autor:
Florian Dick, Henning Rattunde, Nicolas Diehm, Iris Baumgartner, Ralph Kickuth, Brigitta Gahl, Dai-Do Do, Jürg Schmidli
Publikováno v:
Journal of vascular surgery. 45(2)
BackgroundIntegrity of the abdominal aortic aneurysm (AAA) neck is crucial for the long-term success of endovascular AAA repair (EVAR). However, suitable tools for reliable assessment of changes in small aortic volumes are lacking. The purpose of thi
Autor:
Henning Rattunde, Hugo A. Katus, Wolfgang-Michael Franz, Oliver J. Müller, Mathias Lange, Warner S. Simonides, Cordula Bittner, Norbert Frey, Matthias A. Müller, Hans Peter Lorenzen
Publikováno v:
Müller, O J, Lange, M, Rattunde, H, Lorenzen, H P, Müller, M, Frey, N, Bittner, C, Simonides, W, Katus, H A & Franz, W M 2003, ' Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload ', Cardiovascular Research, vol. 59, no. 2, pp. 380-389 . https://doi.org/10.1016/S0008-6363(03)00429-2
Cardiovascular Research, 59(2), 380-389. Oxford University Press
Cardiovascular Research, 59(2), 380-389. Oxford University Press
Objective: The activity of sarcoplasmic reticulum Ca2+-ATPase (SERCA) is reduced in the failing myocardium. Therefore, transfer of SERCA2a cDNA is considered as a therapeutical approach. The aim of this study was analysis of the long-term effect of S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08cfd15ef08e55315bc587bd283263b6
https://research.vumc.nl/en/publications/3fa6601c-0497-48ea-8a45-105d57ad2399
https://research.vumc.nl/en/publications/3fa6601c-0497-48ea-8a45-105d57ad2399
Autor:
Hans-Juergen Woerle, A. Mithal, Jenny Manassie, Uli C. Broedl, Russell Jones, Anthony H. Barnett, B. Gibelin, Henning Rattunde
Publikováno v:
Diabetes & Metabolism. 40:A101
Introduction Cette etude (phase III) de 52 semaines (S) explore l'efficacite et la securite d'empagliflozine (EMPA) en addition au traitement existant chez des patients DT2 avec IR Patients et methodes Suivant leur niveau de fonction renale (eGFR +)